Related Experiment Videos
[Therapeutic approach to pulmonary embolism]
C Phlippoteau1, P Girard, D Musset
1Service de Pneumologie, Hôpital Antoine-Béclère, Clamart.
Journal Des Maladies Vasculaires
|January 1, 1989
Summary
Pulmonary embolism treatment primarily involves heparin and oral anticoagulants. Adjunctive therapies like fibrinolysis or vena cava interruption are used in specific severe cases, demonstrating a low mortality rate.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Surgery
Context:
- Pulmonary embolism (PE) is a significant cause of morbidity and mortality.
- Standardized treatment protocols are crucial for effective PE management.
- Retrospective analysis allows for evaluation of established therapeutic approaches.
Purpose:
- To retrospectively evaluate the treatment outcomes for 196 pulmonary embolism cases.
- To assess the efficacy and safety of standardized therapeutic strategies for PE.
- To analyze the role of adjunctive treatments in managing severe PE.
Summary:
- The standard treatment for most pulmonary embolism patients (74%) included intravenous heparin followed by oral anticoagulants.
- Fibrinolysis with urokinase was administered in 14% of massive PE cases with shock, showing no severe bleeding complications.
- Inferior vena cava interruption was employed in 29% of cases due to anticoagulation contraindications or failure.
- Overall, only one death was recorded in the study cohort, indicating a favorable outcome.
Impact:
- This study highlights the effectiveness of a standardized, multi-modal treatment approach for pulmonary embolism.
- The findings support the use of fibrinolysis and vena cava interruption as safe and viable options in specific PE patient subgroups.
- The low mortality rate suggests successful management strategies for pulmonary embolism in the evaluated cohort.